. 2016 Mar 11;156:361–370. doi: 10.1007/s10549-016-3734-y

Table 3.

Relative survival

	N of observed deaths/N of expected deaths	Relative survival at 10 years (%)	RER	95 % CI		p**	RER*	95 % CI		p**
	N of observed deaths/N of expected deaths	Relative survival at 10 years (%)	RER	Lower	Upper	p**	RER*	Lower	Upper	p**
HER2
Negative: 0/1+	712/536	84	1 (Reference)				1 (Reference)
2+	135/105	88	0.91	0.46	1.82	0.796	0.78	0.45	1.35	0.373
3+	69/22	48	4.75	3.10	7.28	<0.001	2.07	1.26	3.39	0.004
PIK3CA
Negative	344/250	82	1 (Reference)				1 (Reference)
Positive	149/105	81	0.94	0.50	1.76	0.855	1.24	0.78	2.01	0.194

* Adjusted for age, morphology, grade, hormone receptor status, tumour stage, type of breast surgery, type of axillary surgery, radiotherapy, endocrine therapy, chemotherapy

** p values in bold font indicate a statistically significant difference between the groups at the p level of <0.05